Logo

Novartis Hires BioVision to Find Clinically Relevant Peptides

Dec 09, 2004

NEW YORK, Dec. 9 (GenomeWeb News) - BioVision will evaluate clinical samples provided by Switzerland-based Novartis Pharmaceuticals as part of a service agreement, BioVision said today.

 

Germany-based BioVision hopes to find and identify clinically relevant peptides, the company said.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.